Sensei Biotherapeutics repurchases 4.45M shares from Apeiron at $1.58/sh, ends proxy contest

Sensei Biotherapeutics, Inc.

Company to buy 4,454,248 shares from Apeiron Parties at $1.58/share, eliminating their entire beneficial ownership.
Apeiron withdraws its March 2023 notice to nominate three directors for the 2023 annual meeting.
Share repurchase does not change previously disclosed cash runway into second half of 2025.
Standstill and voting agreement applies through the earlier of 4 years or 30 days before 2027 annual meeting.
Company plans to initiate Phase 1/2 clinical trial of lead candidate SNS-101 in mid-2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sensei Biotherapeutics, Inc. entered into Purchase Agreement with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the "Apeiron Parties") (effective 2023-05-23).

Action: entry
Counterparty: Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the "Apeiron Parties")
Effective: 2023-05-23

Exact text from the filing

On May 23, 2023, Sensei Biotherapeutics, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the “Apeiron Parties”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-151834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.